Table S4 (PDF) Table S5 (PDF) Text S1 (DOC) Deficiencies causing a decline in DA. Primers. Brief summary of screen results. Acknowledgments The authors would like to thank: Christiane Fahlbusch (Dept. of Neurodegeneration and Restorative Research, Georg-August University References 1. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26: 81–104. 2. Marsden CD (1983) Neuromelanin and Parkinson’s disease. J Neural Transm Suppl 19: 121–141. 3. Lee FJ, Liu F (2008) Genetic factors involved in the pathogenesis of Parkinson’s disease. Brain Res Rev 58: 354–364. 4. Keeney PM, Xie J, Capaldi RA, Bennett JP, Jr. (2006) Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26: 5256–5264. 5. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, et al. (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54: 823–827. 6. Mizuno Y, Ikebe S, Hattori N, Nakagawa-Hattori Y, Mochizuki H, et al. (1995) Role of mitochondria in the etiology and pathogenesis of Parkinson’s disease. Biochim Biophys Acta 1271: 265–274. 7. Semchuk KM, Love EJ, Lee RG (1992) Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 42: 1328–1335. 8. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, et al. (1997) Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 48: 1583–1588. 9. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B (2009) Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 169: 919–926. 10. Wood-Kaczmar A, Gandhi S, Wood NW (2006) Understanding the molecular causes of Parkinson’s disease. Trends in Molecular Medicine 12: 521–528. 11. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha- Synuclein locus triplication causes Parkinson’s disease. Science 302: 841. 12. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364: 1167–1169. 13. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, et al. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55: 174–179. 14. Fuchs J (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68: 916–922. 15. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839–840. 16. Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, et al. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86: 165–172. 17. Smith WW, Jiang H, Pei Z, Tanaka Y, Morita H, et al. (2005) Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 14: 3801–3811. 18. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, et al. (2007) Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 170: 658–666. 19. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, et al. (2006) Parkinson’s Disease {alpha}-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death. J Neurosci 26: 41–50. 20. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, et al. (2000) {alpha}- Synuclein Promotes Mitochondrial Deficit and Oxidative Stress. Am J Pathol 157: 401–410. 21. Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s disease. Nature 404: 394–398. 22. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P (2002) alpha - Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci U S A 99: 10813–10818. 23. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, et al. (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130: 799–815. 24. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571–576. TRAP1 Mitigates a-Synuclein Toxicity Go¨ttingen, Germany) for excellent technical assistance and the laboratory of Dr. Sebastian K u¨gler and technician Ulrike Schoel (Dept. of Neurology, Viral Vector Laboratory, Georg-August University Go¨ ttingen, Germany) for preparation of rat cortical neurons used in the study. Author Contributions Conceived and designed the experiments: EKB AV KFW JBS. Performed the experiments: EKB EG AKL JPT PK BF AR. Analyzed the data: EKB AV KFW JBS. Wrote the paper: EKB AV JBS. 25. Volles MJ, Lansbury JPT (2007) Relationships between the Sequence of [alpha]- Synuclein and its Membrane Affinity, Fibrillization Propensity, and Yeast Toxicity. Journal of Molecular Biology 366: 1510–1522. 26. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292–1295. 27. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, et al. (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autoph- agy. J Clin Invest 118: 777–788. 28. Petrucelli L, O’Farrell C, Lockhart PJ, Baptista M, Kehoe K, et al. (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36: 1007–1019. 29. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21: 9549–9560. 30. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, et al. (2003) Aggregated and monomeric alpha-synuclein bind to the S69 proteasomal protein and inhibit proteasomal function. J Biol Chem 278: 11753–11759. 31. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, et al. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 10: 919–926. 32. Li WW, Yang R, Guo JC, Ren HM, Zha XL, et al. (2007) Localization of alpha- synuclein to mitochondria within midbrain of mice. Neuroreport 18: 1543–1546. 33. Liu G, Zhang C, Yin J, Li X, Cheng F, et al. (2009) alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci Lett 454: 187–192. 34. Loeb V, Yakunin E, Saada A, Sharon R. The Transgenic Overexpression of a- Synuclein and Not Its Related Pathology Associates with Complex I Inhibition. Journal of Biological Chemistry 285: 7334–7343. 35. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P (2008) Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 65: 1272–1284. 36. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P (2009) Alpha- synuclein overexpression and aggregation exacerbates impairment of mitochon- drial functions by augmenting oxidative stress in human neuroblastoma cells. The International Journal of Biochemistry & Cell Biology 41: 2015–2024. 37. Shavali S, Brown-Borg HM, Ebadi M, Porter J (2008) Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett 439: 125–128. 38. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283: 9089–9100. 39. Pridgeon JW, Olzmann JA, Chin L-S, Li L (2007) PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1. PLoS Biol 5: e172. doi:10.1371/journal.pbio.0050172. 40. Muqit MM, Feany MB (2002) Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat Rev Neurosci 3: 237–243. 41. Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, et al. (2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson’s disease models. EMBO J 28: 3256–3268. 42. Chen J, Shi X, Padmanabhan R, Wang Q, Wu Z, et al. (2008) Identification of novel modulators of mitochondrial function by a genome-wide RNAi screen in Drosophila melanogaster. Genome Res 18: 123–136. 43. Du G, Liu X, Chen X, Song M, Yan Y, et al. Drosophila Histone Deacetylase 6 Protects Dopaminergic Neurons Against {alpha}-Synuclein Toxicity by Promoting Inclusion Formation. Mol Biol Cell E10-03-0200. 44. Bilen J, Bonini NM (2007) Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet 3: e177. doi:10.1371/journal.p- gen.0030177. PLoS Genetics | www.plosgenetics.org 14 February 2012 | Volume 8 | Issue 2 | e1002488